查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2138411

細胞遺傳學市場規模、佔有率和行業分析：按產品、技術、應用、最終用戶和地區分類－全球預測至2036年

Cytogenetics Market Size, Share, and Industry Analysis by Offering, Technique, Application, End User, and Geography - Global Forecast to 2036
出版日期: | 出版商: Meticulous Research | 英文 210 Pages | 訂單完成後即時交付

價格

全球細胞遺傳學市場預計在2025年達到31.04億美元，2026年達到33.515億美元。預計到2036年，該市場規模將達到75.082億美元，在預測期（2026-2036年）內複合年成長率（CAGR）為8.4%。本報告透過檢驗染色體分析、染色體畸變、產前和基因檢測、腫瘤診斷、細胞基因組學技術、自動化分析、競爭趨勢以及臨床診斷和生命科學領域的未來成長機遇，對不斷發展的細胞遺傳學市場進行了全面評估。

細胞遺傳學涵蓋用於分析染色體並識別異常（例如染色體多餘片段、缺失、斷裂、易位、重複以及遺傳物質的亞顯微增減）的耗材、儀器、軟體和服務。此市場包括核型分析、螢光雜合反應(FISH)、比較基因組雜合反應(CGH)（包括染色體微陣列）以及其他細胞遺傳學技術，例如基於光學基因組圖譜和定序的拷貝數分析。這些技術支持產前和產後染色體異常的診斷、白血病、淋巴瘤和骨髓瘤的分類和後續觀察、不孕症和流產的評估以及靶向癌症療法的開發。

此市場成長的主要促進因素包括染色體異常和遺傳疾病盛行率的上升、癌症（尤其是血液系統惡性腫瘤）負擔的加重、人口老化和孕婦年齡的成長，以及自動化和人工智慧輔助等細胞遺傳學分析技術的進步。此外，光學基因組圖譜和其他細胞基因組學技術的引入、基於骨髓惡性腫瘤雜交（FISH）的伴隨診斷在標靶治療中的廣泛應用，以及細胞遺傳學工作流程的數位化，都進一步推動了市場成長。已建立的產前檢測、發育障礙、不孕症、復發性流產和癌症分型等臨床路徑也支持了對細胞遺傳學檢測的持續需求。

本報告透過評估所提供的服務類型、細胞遺傳學方法、臨床和研究應用、終端用戶、技術應用、檢查室自動化、監管趨勢、保險報銷條件以及影響行業成長的競爭策略，提供詳盡的市場分析。報告評估了染色體微陣列、螢光原位雜合技術（FISH）、核型分析、光學基因組圖譜繪製、拷貝數變異測序（CNV-seq）、人工智慧影像分析、自動化掃描和檢查室軟體如何提高診斷準確性、工作流程效率、報告速度和結果解讀。該研究還提供策略性市場預測、細分市場洞察和區域分析，以支持明智的業務、投資、產品開發和市場進入決策。

市場動態

染色體異常和遺傳疾病的普遍存在仍然是細胞遺傳學市場的主要驅動力之一。染色體異常與出生缺陷、發育障礙、不孕症、復發性流產和罕見疾病密切相關，因此對產前、產後和體質細胞遺傳學檢測的需求日益成長。雖然染色體微陣列技術已被廣泛用於評估發育障礙和出生缺陷，但染色體分析（染色體分型）和螢光原位雜合技術（FISH）在識別非整倍體、平衡重排、嵌合體和靶向染色體改變方面仍然發揮著至關重要的作用。

全球癌症負擔的日益加重進一步加速了市場滲透。細胞遺傳學分析在白血病、淋巴瘤和多發性骨髓瘤等骨髓惡性腫瘤的診斷、分型、風險分層和後續觀察中發揮核心作用。此外，FISH技術用於檢測具有臨床意義的擴增和重排，例如HER2擴增和ALK重排，這使得基於FISH的伴隨診斷對於某些標靶癌症治療至關重要。隨著癌症治療越來越依賴生物標記物，對細胞遺傳學探針、晶片、儀器、軟體和專業檢測服務的需求也不斷成長。

人口老化和孕婦年齡的成長推動了細胞遺傳學檢測需求的增加。雖然高齡產婦會增加染色體異常的風險，但老化也會導致癌症和其他遺傳疾病的發生率升高。產前保健、不孕症評估、復發性流產和生殖醫學等領域的現有檢測流程，持續推動對核型分析、螢光原位雜合技術（FISH）、染色體微陣列和新型細胞基因組分析方法的需求。

自動化和人工智慧輔助細胞遺傳學分析的技術進步正在重塑檢查室的工作流程。傳統的核型分析耗時費力，需要訓練有素的技術人員進行染色體的檢測、分割、分類和確認。人工智慧輔助核型分析、自動中期檢測、數位成像和獨立於掃描儀的分析軟體可以減少人工操作時間，提高效率，並獲得更一致的結果。因此，軟體在細胞遺傳學領域的重要性日益凸顯，尤其是在檢查室面臨人員短缺和檢測量不斷增加的情況下。

光學基因組圖譜和其他全基因組技術正在開啟廣闊的應用前景。光學基因組圖譜能夠以比傳統染色體分析更高的解析度檢測結構變異，並正朝著骨髓惡性腫瘤的臨床應用方向發展。基於定序的拷貝數分析，包括CNV-seq，也正在被評估用於產前和產後篩檢。雖然這些方法可以提高檢測拷貝數變異和結構變異的準確性，但它們通常與FISH和染色體分析聯合使用，以進行標靶確認、平衡重排檢測或低水平嵌合體的檢測。

儘管市場環境有利，但訓練有素的細胞遺傳學技術人員和實驗室管理人員短缺仍然是一項重大挑戰。手動進行核型分析對每個中期細胞都非常耗時，限制了單一技術人員能夠處理的病例數。人員流動率上升、檢查室人員短缺以及專業知識獲取方面的差異，都可能延誤結果報告並阻礙產能擴張，尤其是在小規模的檢查室和新興市場。

監管要求和技術變革也在影響市場發展。在歐洲，許多FISH探針試劑盒根據體外診斷法規被歸類為C類醫療設備醫療設備，需要在適用的過渡期內獲得認證。認證機構的處理能力、品管要求以及認證所需的成本和時間可能會導致供應集中在大公司手中，這可能會迫使小規模供應商退出小批量生產。此外，定序正在逐漸取代染色體微陣列，成為某些適應症的第一線檢測方法，這對現有的細胞遺傳學技術構成了新的壓力。

儘管如此，人工智慧分析軟體、自動化影像處理、經認證的FISH探針產品線、光學基因組圖譜繪製服務、基於定序的細胞遺傳學、腫瘤伴隨診斷以及亞太地區產前和基因檢測的擴展，都為該市場帶來了巨大的機會。提供整合化、檢驗、高通量且易於解讀的解決方案的公司有望從細胞遺傳學工作流程的持續現代化中獲益。

細分市場分析

本報告按產品/服務、技術、應用、最終用戶和地區提供詳細的市場分析，使相關人員能夠識別染色體分析、產前診斷、腫瘤學、基因組醫學、檢查室自動化和細胞遺傳學檢測的成長機會和發展趨勢。

目錄

第1章：引言

第2章：調查方法

第3章執行摘要

第4章 市場洞察

  • 影響市場成長的因素
    • 促進因素
      • 染色體異常和遺傳疾病的普遍存在推動了市場成長
      • 癌症，特別是骨髓惡性腫瘤的日益加重，正在推動市場成長。
      • 人口老化和生育年齡延遲是推動市場成長的主要因素。
      • 自動化和人工智慧驅動的細胞遺傳學分析技術的進步正在推動市場成長。
    • 抑制因子
      • 以基於定序的檢測方法取代染色體微陣列正在抑制市場成長。
      • 訓練有素的細胞遺傳學專家短缺和勞動密集工作流程阻礙了市場成長。
      • 對基因資料安全性和隱私性的擔憂阻礙了市場成長。
    • 機會
      • 光學基因組作圖和細胞基因組分析技術的應用正在創造成長機會。
      • 新興經濟體創造成長機遇
      • 對標靶治療和伴隨診斷的日益重視正在創造成長機會。
      • 細胞遺傳學工作流程的數位化正在創造成長機會。
    • 任務
      • 過渡到歐盟體外診斷醫療設備法規
      • 缺乏針對新技術的標準化方法
      • 研究預算和診斷定價面臨壓力
      • 細胞遺傳學檢測的保險報銷複雜且各不相同
  • 主要趨勢
    • 從標靶檢測轉向全基因組細胞遺傳學檢測
    • 產前診斷中基於定序的拷貝數分析的興起
    • 光基因組圖譜的臨床應用
    • 人工智慧和數位細胞遺傳學
    • 長讀長定定序用於結構突變檢測
    • 染色體構象捕獲（3C）在細胞遺傳學的應用
  • 監管分析
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 價值鏈分析
    • 研究與開發
    • 生產製造和監管認證
    • 分配
    • 檢驗與解釋
    • 最終用途

第5章：細胞遺傳學市場評估：依產品/服務分類

  • 消耗品
    • 試劑盒和試劑
      • 檢測套組
      • 探測
      • 其他試劑
    • 其他消耗品
  • 裝置
  • 軟體
  • 服務

第6章：細胞遺傳學市場評估：依技術分類

  • 比較基因雜合反應
  • 螢光原位雜合反應
  • 核型分析
  • 其他技術

第7章：細胞遺傳學市場評估：按應用領域分類

  • 臨床應用
    • 產前檢測和基因檢測
    • 腫瘤學
    • 其他臨床用途
  • 研究用途

第8章：細胞遺傳學市場評估：按最終用戶分類

  • 臨床和診斷實驗室
  • 製藥和生物技術公司
  • 研究和學術機構
  • 其他最終用戶

第9章：細胞遺傳學市場評估：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太國家
  • 拉丁美洲
  • 中東和非洲

第10章 競爭格局

  • 關鍵成長策略
  • 競爭性標竿分析
  • 競爭對手儀錶板
    • 產業領導者
    • 市場差異化因素
    • 先鋒公司
    • 新興企業
  • 2025年市佔率分析
    • Thermo Fisher Scientific Inc.（US）
    • F. Hoffmann-La Roche Ltd（Switzerland）
    • Leica Biosystems（Danaher Corporation）（Germany）

第11章：公司簡介

  • Thermo Fisher Scientific Inc.（US）
  • Abbott Laboratories（US）
  • Agilent Technologies, Inc.（US）
  • Revvity, Inc.（US）
  • Applied Spectral Imaging（US）（A ZYTOMICS Company）
  • Bio-Rad Laboratories, Inc.（US）
  • Sysmex Corporation（Japan）
  • Illumina, Inc.（US）
  • F. Hoffmann-La Roche Ltd（Switzerland）
  • Leica Biosystems（Danaher Corporation）（US）
  • Quest Diagnostics Incorporated（US）

第12章附錄

Product Code: MRHC - 1041446

The global Cytogenetics Market was valued at USD 3,100.4 million in 2025 and is estimated to reach USD 3,351.5 million in 2026. The market is projected to reach USD 7,508.2 million by 2036, registering a CAGR of 8.4% during the forecast period (2026-2036). This report provides a comprehensive assessment of the evolving cytogenetics market by examining chromosome analysis, chromosomal abnormalities, prenatal and genetic testing, oncology diagnostics, cytogenomic technologies, automated analysis, competitive developments, and future growth opportunities across clinical diagnostics and life sciences.

Cytogenetics comprises the consumables, instruments, software, and services used to analyze chromosomes and identify abnormalities such as extra, missing, broken, deleted, rearranged, or duplicated chromosomes and submicroscopic gains and losses of genetic material. The market includes karyotyping, fluorescence in situ hybridization, comparative genomic hybridization including chromosomal microarrays, and other cytogenomic techniques such as optical genome mapping and sequencing-based copy number analysis. These technologies support the diagnosis of chromosomal disorders before and after birth, classification and monitoring of leukemias, lymphomas, and myelomas, evaluation of infertility and pregnancy loss, and the development of targeted cancer therapies.

The growth of this market is mainly driven by the prevalence of chromosomal abnormalities and genetic disorders, the rising burden of cancer, particularly hematologic malignancies, the aging population and rising maternal age, and technological advancements in automated and AI-assisted cytogenetic analysis. In addition, the adoption of optical genome mapping and other cytogenomic technologies, the growing use of FISH-based companion diagnostics for targeted cancer therapies, and the digitization of cytogenetic workflows are further supporting market growth. Established clinical pathways for prenatal testing, developmental disorders, infertility, recurrent pregnancy loss, and cancer classification are sustaining recurring demand for cytogenetic tests.

This report delivers an in-depth analysis of the market by evaluating offering types, cytogenetic techniques, clinical and research applications, end users, technology adoption, laboratory automation, regulatory developments, reimbursement conditions, and competitive strategies shaping industry growth. It assesses how chromosomal microarrays, FISH, karyotyping, optical genome mapping, CNV-seq, AI-assisted image analysis, automated scanning, and laboratory software are improving diagnostic resolution, workflow productivity, turnaround time, and interpretation. The study also provides strategic market forecasts, segment-level insights, and regional analysis to support informed business, investment, product development, and market-entry decisions.

Market Dynamics

The prevalence of chromosomal abnormalities and genetic disorders remains one of the primary drivers of the cytogenetics market. Chromosomal conditions are associated with birth defects, developmental disorders, infertility, recurrent pregnancy loss, and rare diseases, creating demand for prenatal, postnatal, and constitutional cytogenetic testing. Chromosomal microarray is widely used in the evaluation of developmental disorders and congenital anomalies, while karyotyping and FISH remain important for identifying aneuploidies, balanced rearrangements, mosaicism, and targeted chromosomal changes.

The rising global burden of cancer is further accelerating market adoption. Cytogenetic analysis is central to the diagnosis, classification, risk stratification, and monitoring of hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. FISH is also used to detect clinically important amplifications and rearrangements such as HER2 amplification and ALK rearrangements, and FISH-based companion diagnostics are required for certain targeted cancer therapies. As oncology treatment becomes increasingly biomarker-driven, demand for cytogenetic probes, arrays, instruments, software, and specialized laboratory services is expanding.

The aging population and rising maternal age are supporting additional demand for cytogenetic testing. Older maternal age is associated with increased risk of chromosomal abnormalities, while aging populations contribute to higher incidence of cancer and other genetic conditions. Established testing pathways in prenatal care, infertility evaluation, recurrent pregnancy loss, and reproductive medicine continue to generate demand for karyotyping, FISH, chromosomal microarrays, and emerging cytogenomic methods.

Technological advancements in automated and AI-assisted cytogenetic analysis are reshaping laboratory workflows. Conventional karyotyping is labor-intensive and requires trained technologists to detect, segment, classify, and review chromosomes. AI-assisted karyotyping, automated metaphase detection, digital imaging, and scanner-agnostic analysis software can reduce hands-on time, improve productivity, and support more consistent interpretation. Software is therefore becoming an increasingly important part of the cytogenetics ecosystem, particularly as laboratories face staffing constraints and growing test volumes.

Optical genome mapping and other genome-wide techniques are creating significant opportunities. Optical genome mapping can detect structural variants at higher resolution than conventional karyotyping and is moving toward clinical adoption in hematologic malignancies. Sequencing-based copy number analysis, including CNV-seq, is also being evaluated in prenatal and postnatal testing. These methods can improve discovery of copy-number changes and structural variants, although they are often used alongside FISH and karyotyping for targeted confirmation and detection of balanced rearrangements or low-level mosaicism.

Despite favorable market conditions, the shortage of trained cytogenetic technologists and laboratory directors remains an important challenge. Manual karyotyping can require substantial time per metaphase, limiting the number of cases each technologist can complete. Rising retirement rates, constrained laboratory staffing, and uneven access to specialized expertise may delay results and restrict the expansion of testing capacity, particularly in smaller laboratories and emerging markets.

Regulatory requirements and technology transition also influence market development. In Europe, many FISH probe kits are Class C devices under the In Vitro Diagnostic Regulation and must obtain certification within the applicable transition period. Notified-body capacity, quality-management requirements, and the cost and time required for certification may concentrate supply among larger companies and lead smaller suppliers to withdraw low-volume products. In addition, sequencing is gradually replacing chromosomal microarrays as a first-tier test in some indications, creating substitution pressure for established cytogenetic technologies.

The market nevertheless presents substantial opportunities through AI-based analysis software, automated imaging, certified FISH probe portfolios, optical genome mapping services, sequencing-based cytogenomics, oncology companion diagnostics, and expanding prenatal and genetic testing in Asia-Pacific. Companies that provide integrated, validated, high-throughput, and easy-to-interpret solutions are expected to be well positioned to benefit from the continued modernization of cytogenetic workflows.

Segment Analysis

The report provides detailed market analysis across offering, technique, application, end user, and geography, enabling stakeholders to identify high-growth opportunities and evolving trends in chromosome analysis, prenatal diagnostics, oncology, genomic medicine, laboratory automation, and cytogenomic testing.

Based on offering, the market is segmented into Consumables, comprising kits and reagents, testing kits, probes, and other reagents, as well as Other Consumables, Instruments, Software, and Services. Consumables are expected to account for the largest market share of 64.4% in 2026, attributed to the recurring use of FISH probe kits, chromosomal microarray kits, culture reagents, slides, and other materials in cytogenetic testing. However, Software is projected to register the highest CAGR of 10.3% during the forecast period, driven by AI-assisted karyotyping, automated FISH image analysis, digital workflows, and interpretation software for genome-wide cytogenomic data. Instruments are projected to grow more slowly as capital budgets remain constrained.

Based on technique, the market is segmented into Comparative Genomic Hybridization, Fluorescence In Situ Hybridization, Karyotyping, and Other Techniques. Comparative Genomic Hybridization, including chromosomal microarrays, is expected to account for the largest share of 56.3% of the market in 2026. The large share of this segment is supported by the use of chromosomal microarrays as a first-tier test for developmental disorders and congenital anomalies, as well as their ability to detect submicroscopic copy-number changes. However, Other Techniques, including optical genome mapping and sequencing-based copy number analysis, are projected to register the highest CAGR of 16.8% during the forecast period. Karyotyping is projected to register the lowest CAGR of 5.4% but remains important for balanced rearrangements, mosaicism, and single-cell chromosome analysis.

Based on application, the market is segmented into Clinical Applications, comprising prenatal and genetic testing, oncology, and other clinical applications, and Research Applications. Clinical Applications are expected to account for the larger share of 83.4% of the cytogenetics market in 2026 and are projected to register the higher CAGR of 8.6% during the forecast period. Prenatal & Genetic Testing is expected to account for the largest share within clinical applications, supported by testing for chromosomal abnormalities, congenital anomalies, infertility, and recurrent pregnancy loss. Oncology is projected to register the highest CAGR of 10.4%, driven by the classification of hematologic malignancies, FISH-based companion diagnostics, and increasing use of cytogenetic biomarkers in targeted cancer treatment.

Based on end user, the market is segmented into Clinical & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, and Other End Users. Clinical & Diagnostic Laboratories are expected to account for the largest share of 37.4% of the market in 2026, reflecting the high volume of prenatal, postnatal, genetic, and oncology cytogenetic tests performed by hospital and reference laboratories. This segment is also projected to register the highest CAGR of 9.2% during the forecast period, driven by clinical testing volumes, accreditation requirements, automation, and expanding access to cytogenomic methods. Research & Academic Institutes are projected to grow more slowly because of pressure on public research funding.

Regional Analysis

The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional evaluations consider birth cohorts, cancer burden, genetic disease prevalence, prenatal care, laboratory infrastructure, reimbursement, national screening programs, regulatory requirements, technology adoption, staffing, and investments influencing market growth.

North America is expected to account for the largest share of 46.0% of the global Cytogenetics Market in 2026. The region is home to leading cytogenetics suppliers, including Thermo Fisher Scientific, Abbott, Agilent Technologies, Illumina, Bio-Rad, and Applied Spectral Imaging, as well as large reference laboratories such as Quest Diagnostics and Labcorp. High cancer incidence, extensive prenatal and reproductive medicine services, strong clinical laboratory infrastructure, and the introduction of a Category I CPT code covering optical genome mapping in genetic disorders are supporting regional growth.

Europe is expected to account for the second-largest share of 27.8% of the cytogenetics market in 2026. The region has a large network of hospital cytogenetics laboratories and leading suppliers such as Leica Biosystems and MetaSystems in Germany, OGT in the U.K., and Roche in Switzerland. The In Vitro Diagnostic Regulation is a defining feature of the regional market, as many FISH probe kits must obtain certification within the applicable transition period. Germany is expected to account for the largest share of the European market.

Asia-Pacific is projected to register the highest CAGR of 9.1% during the forecast period. The region includes large birth cohorts in China and India, rapidly aging populations in Japan and South Korea, and a substantial share of global leukemia cases. China is expected to account for the largest share of the regional market in 2026 and is projected to register the highest CAGR of any country, at 10.2%. Expanding prenatal care, growing cancer diagnosis, national genome and screening programs, investments in laboratory infrastructure, and the adoption of optical genome mapping and sequencing-based methods are expected to create additional opportunities.

Latin America is expected to account for a share of 3.8% of the cytogenetics market in 2026. The regional market is driven by growing cancer and prenatal care, concentrated in private laboratories and reference hospitals in large cities. The region recorded approximately 41,006 new leukemia cases in 2022, supporting demand for oncology cytogenetics. However, public reimbursement remains limited and many complex tests are referred to large private laboratories. Brazil is expected to account for the largest regional share.

The Middle East & Africa is expected to account for a share of 2.0% of the cytogenetics market in 2026. Growth is supported by the high prevalence of chromosomal and recessive disorders associated with consanguinity in Gulf states, as well as premarital and newborn screening programs. The Saudi Genome Program and the Emirati Genome Programme are strengthening genomic medicine infrastructure, while cytogenetic capacity in much of Africa remains concentrated in a limited number of reference centers.

Competitive Landscape

The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of leading market participants, their kits and reagent portfolios, FISH probes, chromosomal microarray solutions, karyotyping systems, imaging instruments, software, optical genome mapping platforms, testing services, product launches, acquisitions, partnerships, regulatory certifications, geographic expansion initiatives, research and development investments, and recent business developments.

Competitive benchmarking enables stakeholders to evaluate companies based on test menu breadth, assay performance, resolution, turnaround time, automation, AI capabilities, image analysis, clinical validation, regulatory certification, service support, installed base, and pricing. The study also analyzes how market participants are responding to competition between arrays, FISH, and karyotyping suppliers and emerging sequencing and optical genome mapping technologies.

The five leading companies-Thermo Fisher Scientific, Roche, Leica Biosystems through Danaher, Agilent Technologies, and Illumina-held an assessed 57% to 66% of the cytogenetics market in 2025, with Thermo Fisher Scientific holding the leading assessed share of 21% to 23%. Product launches, acquisitions, and partnerships were among the most common growth strategies. Key companies profiled in the report include Thermo Fisher Scientific Inc., Abbott Laboratories, Agilent Technologies, Inc., Revvity, Inc., Applied Spectral Imaging, Bio-Rad Laboratories, Inc., Sysmex Corporation, Illumina, Inc., F. Hoffmann-La Roche Ltd, Leica Biosystems, and Quest Diagnostics Incorporated.

How This Report Helps

Provides accurate market size estimates and long-term forecasts for the global cytogenetics market.

Evaluates the impact of chromosomal abnormalities, cancer burden, maternal age, prenatal testing, and genetic disease prevalence on market growth.

Identifies high-growth opportunities across offerings, techniques, applications, end users, and geographic regions.

Analyzes emerging trends in AI-assisted karyotyping, automated imaging, optical genome mapping, CNV-seq, digital cytogenetics, and sequencing-based cytogenomics.

Assesses the influence of laboratory staffing, IVDR certification, reimbursement, technology substitution, clinical validation, and regulatory requirements on adoption.

Benchmarks leading companies based on product portfolios, assay performance, automation capabilities, AI integration, clinical positioning, regulatory certifications, and competitive presence.

Supports product development, investment planning, partnership evaluation, market entry, laboratory expansion, and business growth strategies.

Delivers actionable market intelligence for cytogenetics suppliers, diagnostic laboratories, hospitals, pharmaceutical and biotechnology companies, research institutes, clinicians, investors, distributors, and healthcare organizations.

Key Questions Answered

What is the current size of the global cytogenetics market, and how is it expected to evolve through 2036?

Which technological, clinical, regulatory, operational, and economic factors are driving market growth?

What are the major drivers, restraints, opportunities, and challenges influencing industry development?

Which offering, technique, application, end-user, and regional segments are expected to experience the strongest growth?

Why are Consumables expected to account for the largest offering share, and why is Software projected to grow fastest?

How will comparative genomic hybridization, FISH, karyotyping, optical genome mapping, and CNV-seq influence market development?

How are AI-assisted karyotyping, automated imaging, and laboratory software changing cytogenetic workflows?

What role will IVDR certification and regulatory requirements play in the European FISH probe market?

Which geographic markets present the most attractive business opportunities for cytogenetics companies?

How are sequencing-based methods affecting the use of chromosomal microarrays and other conventional techniques?

Who are the leading companies operating in the market, and what competitive strategies are they adopting?

What recent product launches, acquisitions, partnerships, certifications, and technological innovations are shaping the competitive landscape?

How can stakeholders leverage market intelligence from this report to support investment decisions, product development, laboratory planning, competitive benchmarking, and long-term business strategy?

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
    • 2.3.2. Bottom-Up Approach
    • 2.3.3. Top-Down Approach
    • 2.3.4. Growth Forecast
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Drivers
      • 4.2.1.1. Prevalence of Chromosomal Abnormalities and Genetic Disorders Driving Market Growth
      • 4.2.1.2. Rising Burden of Cancer, Particularly Hematologic Malignancies, Driving Market Growth
      • 4.2.1.3. Aging Population and Rising Maternal Age Driving Market Growth
      • 4.2.1.4. Technological Advancements in Automated and AI-Assisted Cytogenetic Analysis Driving Market Growth
    • 4.2.2. Restraints
      • 4.2.2.1. Substitution of Chromosomal Microarrays by Sequencing-Based Tests Restraining Market Growth
      • 4.2.2.2. Shortage of Trained Cytogenetic Staff and Labor-Intensive Workflows Restraining Market Growth
      • 4.2.2.3. Concerns Regarding the Security & Privacy of Genetic Data Restraining Market Growth
    • 4.2.3. Opportunities
      • 4.2.3.1. Adoption of Optical Genome Mapping and Cytogenomic Technologies Generating Growth Opportunities
      • 4.2.3.2. Emerging Economies Generating Growth Opportunities
      • 4.2.3.3. Increasing Focus on Targeted Therapies and Companion Diagnostics Generating Growth Opportunities
      • 4.2.3.4. Digitization of Cytogenetic Workflows Generating Growth Opportunities
    • 4.2.4. Challenges
      • 4.2.4.1. Transition to the EU in Vitro Diagnostic Regulation
      • 4.2.4.2. Lack of Standardized Approaches for Newer Technologies
      • 4.2.4.3. Pressure on Research Budgets and Diagnostic Prices
      • 4.2.4.4. Complex and Uneven Reimbursement for Cytogenetic Tests
  • 4.3. Key Trends
    • 4.3.1. Transition from Targeted to Genome-Wide Cytogenomic Testing
    • 4.3.2. Rise of Sequencing-Based Copy Number Analysis in Prenatal Diagnosis
    • 4.3.3. Clinical Adoption of Optical Genome Mapping
    • 4.3.4. Artificial Intelligence and Digital Cytogenetics
    • 4.3.5. Long-Read Sequencing for Structural Variant Detection
    • 4.3.6. Use of Chromosome Conformation Capture (3C) in Cytogenetics
  • 4.4. Regulatory Analysis
    • 4.4.1. North America
    • 4.4.2. Europe
    • 4.4.3. Asia-Pacific
    • 4.4.4. Latin America
    • 4.4.5. Middle East & Africa
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of Substitutes
    • 4.5.4. Threat of New Entrants
    • 4.5.5. Degree of Competition
  • 4.6. Value Chain Analysis
    • 4.6.1. Research & Development
    • 4.6.2. Manufacturing and Regulatory Certification
    • 4.6.3. Distribution
    • 4.6.4. Testing and Interpretation
    • 4.6.5. End Use

5. Cytogenetics Market Assessment, by Offering

  • 5.1. Overview
  • 5.2. Consumables
    • 5.2.1. Kits & Reagents
      • 5.2.1.1. Testing Kits
      • 5.2.1.2. Probes
      • 5.2.1.3. Other Reagents
    • 5.2.2. Other Consumables
  • 5.3. Instruments
  • 5.4. Software
  • 5.5. Services

6. Cytogenetics Market Assessment, by Technique

  • 6.1. Overview
  • 6.2. Comparative Genomic Hybridization
  • 6.3. Fluorescence In Situ Hybridization
  • 6.4. Karyotyping
  • 6.5. Other Techniques

7. Cytogenetics Market Assessment, by Application

  • 7.1. Overview
  • 7.2. Clinical Applications
    • 7.2.1. Prenatal & Genetic Testing
    • 7.2.2. Oncology
    • 7.2.3. Other Clinical Applications
  • 7.3. Research Applications

8. Cytogenetics Market Assessment, by End User

  • 8.1. Overview
  • 8.2. Clinical & Diagnostic Laboratories
  • 8.3. Pharmaceutical & Biotechnology Companies
  • 8.4. Research & Academic Institutes
  • 8.5. Other End Users

9. Cytogenetics Market Assessment, by Geography

  • 9.1. Overview
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. U.K.
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Rest of Europe
  • 9.4. Asia-Pacific
    • 9.4.1. China
    • 9.4.2. Japan
    • 9.4.3. India
    • 9.4.4. Rest of Asia-Pacific
  • 9.5. Latin America
  • 9.6. Middle East & Africa

10. Competitive Landscape

  • 10.1. Introduction
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Competitive Dashboard
    • 10.4.1. Industry Leaders
    • 10.4.2. Market Differentiators
    • 10.4.3. Vanguards
    • 10.4.4. Emerging Companies
  • 10.5. Market Share Analysis, 2025
    • 10.5.1. Thermo Fisher Scientific Inc. (U.S.)
    • 10.5.2. F. Hoffmann-La Roche Ltd (Switzerland)
    • 10.5.3. Leica Biosystems (Danaher Corporation) (Germany)

11. Company Profiles

  • 11.1. Thermo Fisher Scientific Inc. (U.S.)
    • 11.1.1. Company Overview
    • 11.1.2. Financial Overview
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Developments
    • 11.1.5. SWOT Analysis
  • 11.2. Abbott Laboratories (U.S.)
    • 11.2.1. Company Overview
    • 11.2.2. Financial Overview
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Developments
    • 11.2.5. SWOT Analysis
  • 11.3. Agilent Technologies, Inc. (U.S.)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Overview
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Developments
    • 11.3.5. SWOT Analysis
  • 11.4. Revvity, Inc. (U.S.)
    • 11.4.1. Company Overview
    • 11.4.2. Financial Overview
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Developments
    • 11.4.5. SWOT Analysis
  • 11.5. Applied Spectral Imaging (U.S.) (A ZYTOMICS Company)
    • 11.5.1. Company Overview
    • 11.5.2. Financial Overview
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Developments
    • 11.5.5. SWOT Analysis
  • 11.6. Bio-Rad Laboratories, Inc. (U.S.)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Overview
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Developments
    • 11.6.5. SWOT Analysis
  • 11.7. Sysmex Corporation (Japan)
    • 11.7.1. Company Overview
    • 11.7.2. Financial Overview
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Developments
    • 11.7.5. SWOT Analysis
  • 11.8. Illumina, Inc. (U.S.)
    • 11.8.1. Company Overview
    • 11.8.2. Financial Overview
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Developments
    • 11.8.5. SWOT Analysis
  • 11.9. F. Hoffmann-La Roche Ltd (Switzerland)
    • 11.9.1. Company Overview
    • 11.9.2. Financial Overview
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Developments
    • 11.9.5. SWOT Analysis
  • 11.10. Leica Biosystems (Danaher Corporation) (U.S.)
    • 11.10.1. Company Overview
    • 11.10.2. Financial Overview
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Developments
    • 11.10.5. SWOT Analysis
  • 11.11. Quest Diagnostics Incorporated (U.S.)
    • 11.11.1. Company Overview
    • 11.11.2. Financial Overview
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Developments
    • 11.11.5. SWOT Analysis

12. Appendix

  • 12.1. Available Customization
  • 12.2. Related Reports

LIST OF TABLES

List of Tables

  • Table 1 Key Secondary Sources
  • Table 2 IVDR Transition Milestones for Legacy Class C in Vitro Diagnostic Devices
  • Table 3 Cytogenetics: Key Regulations and Standards
  • Table 4 Global Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 5 Global Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 6 Global Cytogenetics Consumables Market, by Country/Region, 2024-2036 (USD Million)
  • Table 7 Cytogenetics: Selected FISH Probe and Microarray Portfolios, by Company
  • Table 8 Global Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 9 Global Cytogenetics Kits & Reagents Market, by Country/Region, 2024-2036 (USD Million)
  • Table 10 Global Cytogenetics Testing Kits Market, by Country/Region, 2024-2036 (USD Million)
  • Table 11 Global Cytogenetics Probes Market, by Country/Region, 2024-2036 (USD Million)
  • Table 12 Global Cytogenetics Other Reagents Market, by Country/Region, 2024-2036 (USD Million)
  • Table 13 Global Cytogenetics Other Consumables Market, by Country/Region, 2024-2036 (USD Million)
  • Table 14 Cytogenetics: Selected Imaging and Genome-Wide Instrument Platforms
  • Table 15 Global Cytogenetics Instruments Market, by Country/Region, 2024-2036 (USD Million)
  • Table 16 Global Cytogenetics Software Market, by Country/Region, 2024-2036 (USD Million)
  • Table 17 Global Cytogenetics Services Market, by Country/Region, 2024-2036 (USD Million)
  • Table 18 Comparison of Cytogenetic Techniques
  • Table 19 Global Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 20 Global Cytogenetics Market for Comparative Genomic Hybridization, by Country/Region, 2024-2036 (USD Million)
  • Table 21 Global Cytogenetics Market for Fluorescence In Situ Hybridization, by Country/Region, 2024-2036 (USD Million)
  • Table 22 Global Cytogenetics Market for Karyotyping, by Country/Region, 2024-2036 (USD Million)
  • Table 23 Global Cytogenetics Market for Other Techniques, by Country/Region, 2024-2036 (USD Million)
  • Table 24 Global Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 25 Global Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 26 Global Cytogenetics Market for Clinical Applications, by Country/Region, 2024-2036 (USD Million)
  • Table 27 Global Cytogenetics Market for Prenatal & Genetic Testing, by Country/Region, 2024-2036 (USD Million)
  • Table 28 Global Cytogenetics Market for Oncology, by Country/Region, 2024-2036 (USD Million)
  • Table 29 Global Cytogenetics Market for Other Clinical Applications, by Country/Region, 2024-2036 (USD Million)
  • Table 30 Global Cytogenetics Market for Research Applications, by Country/Region, 2024-2036 (USD Million)
  • Table 31 Global Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 32 Global Cytogenetics Market for Clinical & Diagnostic Laboratories, by Country/Region, 2024-2036 (USD Million)
  • Table 33 Global Cytogenetics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2024-2036 (USD Million)
  • Table 34 Global Cytogenetics Market for Research & Academic Institutes, by Country/Region, 2024-2036 (USD Million)
  • Table 35 Global Cytogenetics Market for Other End Users, by Country/Region, 2024-2036 (USD Million)
  • Table 36 Global Cytogenetics Market, by Region, 2024-2036 (USD Million)
  • Table 37 North America: Cytogenetics Market, by Country/Region, 2024-2036 (USD Million)
  • Table 38 North America: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 39 North America: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 40 North America: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 41 North America: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 42 North America: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 43 North America: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 44 North America: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 45 U.S.: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 46 U.S.: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 47 U.S.: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 48 U.S.: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 49 U.S.: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 50 U.S.: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 51 U.S.: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 52 Canada: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 53 Canada: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 54 Canada: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 55 Canada: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 56 Canada: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 57 Canada: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 58 Canada: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 59 Europe: Cytogenetics Market, by Country/Region, 2024-2036 (USD Million)
  • Table 60 Europe: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 61 Europe: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 62 Europe: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 63 Europe: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 64 Europe: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 65 Europe: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 66 Europe: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 67 Germany: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 68 Germany: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 69 Germany: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 70 Germany: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 71 Germany: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 72 Germany: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 73 Germany: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 74 France: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 75 France: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 76 France: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 77 France: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 78 France: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 79 France: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 80 France: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 81 U.K.: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 82 U.K.: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 83 U.K.: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 84 U.K.: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 85 U.K.: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 86 U.K.: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 87 U.K.: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 88 Italy: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 89 Italy: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 90 Italy: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 91 Italy: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 92 Italy: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 93 Italy: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 94 Italy: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 95 Spain: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 96 Spain: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 97 Spain: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 98 Spain: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 99 Spain: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 100 Spain: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 101 Spain: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 102 Rest of Europe: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 103 Rest of Europe: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 104 Rest of Europe: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 105 Rest of Europe: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 106 Rest of Europe: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 107 Rest of Europe: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 108 Rest of Europe: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 109 Asia-Pacific: Cytogenetics Market, by Country/Region, 2024-2036 (USD Million)
  • Table 110 Asia-Pacific: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 111 Asia-Pacific: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 112 Asia-Pacific: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 113 Asia-Pacific: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 114 Asia-Pacific: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 115 Asia-Pacific: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 116 Asia-Pacific: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 117 China: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 118 China: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 119 China: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 120 China: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 121 China: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 122 China: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 123 China: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 124 Japan: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 125 Japan: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 126 Japan: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 127 Japan: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 128 Japan: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 129 Japan: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 130 Japan: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 131 India: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 132 India: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 133 India: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 134 India: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 135 India: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 136 India: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 137 India: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 138 Rest of Asia-Pacific: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 139 Rest of Asia-Pacific: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 140 Rest of Asia-Pacific: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 141 Rest of Asia-Pacific: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 142 Rest of Asia-Pacific: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 143 Rest of Asia-Pacific: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 144 Rest of Asia-Pacific: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 145 Latin America: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 146 Latin America: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 147 Latin America: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 148 Latin America: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 149 Latin America: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 150 Latin America: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 151 Latin America: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 152 Middle East & Africa: Cytogenetics Market, by Offering, 2024-2036 (USD Million)
  • Table 153 Middle East & Africa: Cytogenetics Consumables Market, by Type, 2024-2036 (USD Million)
  • Table 154 Middle East & Africa: Cytogenetics Kits & Reagents Market, by Type, 2024-2036 (USD Million)
  • Table 155 Middle East & Africa: Cytogenetics Market, by Technique, 2024-2036 (USD Million)
  • Table 156 Middle East & Africa: Cytogenetics Market, by Application, 2024-2036 (USD Million)
  • Table 157 Middle East & Africa: Cytogenetics Market for Clinical Applications, by Type, 2024-2036 (USD Million)
  • Table 158 Middle East & Africa: Cytogenetics Market, by End User, 2024-2036 (USD Million)
  • Table 159 Cytogenetics Market: Competitive Benchmarking, by Offering
  • Table 160 Cytogenetics Market: Assessed Market Shares of Leading Companies, 2025
  • Table 161 Thermo Fisher Scientific Inc.: Product Portfolio
  • Table 162 Thermo Fisher Scientific Inc.: Strategic Developments
  • Table 163 Abbott Laboratories: Product Portfolio
  • Table 164 Abbott Laboratories: Strategic Developments
  • Table 165 Agilent Technologies, Inc.: Product Portfolio
  • Table 166 Agilent Technologies, Inc.: Strategic Developments
  • Table 167 Revvity, Inc.: Product Portfolio
  • Table 168 Revvity, Inc.: Strategic Developments
  • Table 169 Applied Spectral Imaging: Product Portfolio
  • Table 170 Applied Spectral Imaging: Strategic Developments
  • Table 171 Bio-Rad Laboratories, Inc.: Product Portfolio
  • Table 172 Bio-Rad Laboratories, Inc.: Strategic Developments
  • Table 173 Sysmex Corporation: Product Portfolio
  • Table 174 Sysmex Corporation: Strategic Developments
  • Table 175 Illumina, Inc.: Product Portfolio
  • Table 176 Illumina, Inc.: Strategic Developments
  • Table 177 F. Hoffmann-La Roche Ltd: Product Portfolio
  • Table 178 F. Hoffmann-La Roche Ltd: Strategic Developments
  • Table 179 Danaher Corporation: Product Portfolio
  • Table 180 Danaher Corporation: Strategic Developments
  • Table 181 Quest Diagnostics Incorporated: Product Portfolio
  • Table 182 Quest Diagnostics Incorporated: Strategic Developments

LIST OF FIGURES

List of Figures

  • Figure 1 Cytogenetics Market Ecosystem
  • Figure 2 Research Process
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 6 Market Sizing and Growth Forecast Approach
  • Figure 7 Global Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 8 Global Cytogenetics Market, by Offering, 2026 vs. 2036 (USD Million)
  • Figure 9 Global Cytogenetics Market, by Technique, 2026 vs. 2036 (USD Million)
  • Figure 10 Global Cytogenetics Market, by Application, 2026 vs. 2036 (USD Million)
  • Figure 11 Global Cytogenetics Market, by End User, 2026 vs. 2036 (USD Million)
  • Figure 12 Cytogenetics Market, by Geography
  • Figure 13 Factors Affecting Market Growth
  • Figure 14 Prevalence of Selected Conditions Assessed with Cytogenetic Testing, U.S. (per 1,000 Births)
  • Figure 15 New Cancer Cases Worldwide, 2022 vs. 2050 (Million)
  • Figure 16 Time Required per Metaphase: Manual vs. AI-Assisted Karyotyping (Minutes)
  • Figure 17 Number of Optical Genome Mapping Studies Presented at ACMG and ESHG Conferences, 2025 vs. 2026
  • Figure 18 IVDR Applications Submitted vs. Certificates Issued (Cumulative, to October 2025)
  • Figure 19 Average Commercial Payer Rates for CPT 81277 (Cytogenomic Neoplasia Microarray), U.S. (USD)
  • Figure 20 Detection Rates of Fetal Chromosomal Abnormalities: CNV-seq vs. Karyotyping (%)
  • Figure 21 Porter's Five Forces Analysis
  • Figure 22 Value Chain Analysis
  • Figure 23 Global Cytogenetics Market, by Offering, 2026 vs. 2036 (USD Million)
  • Figure 24 Global Cytogenetics Consumables Market, by Type, 2026 vs. 2036 (USD Million)
  • Figure 25 Global Cytogenetics Kits & Reagents Market, by Type, 2026 vs. 2036 (USD Million)
  • Figure 26 Bionano Genomics: Revenue, 2024 vs. 2025 (USD Million)
  • Figure 27 Reported Reduction in Karyotyping Analysis Time with Artificial Intelligence (%)
  • Figure 28 Global Cytogenetics Market, by Technique, 2026 vs. 2036 (USD Million)
  • Figure 29 Diagnostic Yield of Chromosomal Microarray vs. Karyotyping (%)
  • Figure 30 Time Required per Metaphase: Manual vs. AI-Assisted Karyotyping (Minutes)
  • Figure 31 Number of Optical Genome Mapping Studies Presented at ACMG and ESHG Conferences, 2025 vs. 2026
  • Figure 32 Global Cytogenetics Market, by Application, 2026 vs. 2036 (USD Million)
  • Figure 33 Global Cytogenetics Market for Clinical Applications, by Type, 2026 vs. 2036 (USD Million)
  • Figure 34 Prevalence of Selected Conditions Assessed with Cytogenetic Testing, U.S. (per 1,000 Births)
  • Figure 35 New Cases of Leukemia and Multiple Myeloma Worldwide, 2022
  • Figure 36 IVF Cycles Reported by SART Member Clinics, U.S., 2022-2024
  • Figure 37 Global Cytogenetics Market, by End User, 2026 vs. 2036 (USD Million)
  • Figure 38 Neogenomics: Clinical Revenue and Test Volume Growth, Q3 2025 (%)
  • Figure 39 New Leukemia Cases Worldwide, by Region, 2022
  • Figure 40 Cytogenetics Market, by Geography
  • Figure 41 Global Cytogenetics Market, by Region, 2026 vs. 2036 (USD Million)
  • Figure 42 North America: Cytogenetics Market, by Country/Region, 2026 vs. 2036 (USD Million)
  • Figure 43 U.S.: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 44 Canada: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 45 Europe: Cytogenetics Market, by Country/Region, 2026 vs. 2036 (USD Million)
  • Figure 46 Germany: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 47 France: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 48 U.K.: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 49 Italy: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 50 Spain: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 51 Rest of Europe: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 52 Asia-Pacific: Cytogenetics Market, by Country/Region, 2026 vs. 2036 (USD Million)
  • Figure 53 China: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 54 Japan: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 55 India: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 56 Rest of Asia-Pacific: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 57 Latin America: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 58 Middle East & Africa: Cytogenetics Market Size, 2024-2036 (USD Million)
  • Figure 59 Cytogenetics Market: Number of Strategic Developments, by Approach, January 2025-SEPTEMBER 2026
  • Figure 60 Cytogenetics Market: Competitive Dashboard
  • Figure 61 Cytogenetics Market: Assessed Market Shares of Leading Companies, 2025 (Midpoint of Range, %)
  • Figure 62 Thermo Fisher Scientific Inc.: Financial Snapshot (2025)
  • Figure 63 Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 64 Abbott Laboratories: Financial Snapshot (2025)
  • Figure 65 Abbott Laboratories: SWOT Analysis
  • Figure 66 Agilent Technologies, Inc.: Financial Snapshot (2025)
  • Figure 67 Agilent Technologies, Inc.: SWOT Analysis
  • Figure 68 Revvity, Inc.: Financial Snapshot (2025)
  • Figure 69 Revvity, Inc.: SWOT Analysis
  • Figure 70 Applied Spectral Imaging: Financial Snapshot (2025)
  • Figure 71 Applied Spectral Imaging: SWOT Analysis
  • Figure 72 Bio-Rad Laboratories, Inc.: Financial Snapshot (2025)
  • Figure 73 Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 74 Sysmex Corporation: Financial Snapshot (2025)
  • Figure 75 Sysmex Corporation: SWOT Analysis
  • Figure 76 Illumina, Inc.: Financial Snapshot (2025)
  • Figure 77 Illumina, Inc.: SWOT Analysis
  • Figure 78 F. Hoffmann-La Roche Ltd: Financial Snapshot (2025)
  • Figure 79 F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 80 Danaher Corporation: Financial Snapshot (2025)
  • Figure 81 Danaher Corporation: SWOT Analysis
  • Figure 82 Quest Diagnostics Incorporated: Financial Snapshot (2025)
  • Figure 83 Quest Diagnostics Incorporated: SWOT Analysis